Collectively, these findings led us to hypothesize that MDH2 may exert a pro-oncogenic function in breast cancer and could serve as a biomarker for diagnosis, treatment, and prognosis in breast cancer patients. This evidence concerns the gene MDH2 and breast carcinoma.